stockrow
Friday 6 November 2026
Export BLTE’s income statement to Excel — free account
Belite Bio, Inc. Sponsored ADR
BLTE Healthcare Biotechnology
- EPS
- −40.0%
- Free cash flow
- +64.7%
Quarter to June 2026, against a year earlier
154.46
11.27
+7.87%
Follow BLTE
Alert me
Belite Bio, Inc. Sponsored ADR (BLTE) Operating cash flow
Belite Bio, Inc. Sponsored ADR's operating cash flow for fiscal 2025 was −$37.0M, compared with −$29.2M in fiscal 2024. Over the past ten years it has ranged from −$37.0M (fiscal 2025) to −$4.4M (fiscal 2020) — the current reading is the lowest in ten years. Belite Bio, Inc. Sponsored ADR ranks 389th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$37.0M | — |
| FY2024 | −$29.2M | — |
| FY2023 | −$29.8M | — |
| FY2022 | −$11.5M | — |
| FY2021 | −$7.5M | — |
| FY2020 | −$4.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Dec 2025 | −$10.4M | — |
| Sep 2025 | −$26.6M | — |
| Dec 2024 | −$4.6M | — |
| Sep 2024 | −$24.6M | — |
| 6 more quarters | Free account |
Against its own ten years
Low −$37.0M
High −$4.4M
Ten-year median
−$20.3M
Current reading's percentile
17
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $91.0M |
| PTCT PTC Therapeutics, Inc. compare | $10.5M |
| BLTE Belite Bio, Inc. Sponsored ADR | −$66.2M |
| ORKA Oruka Therapeutics, Inc. compare | −$100.9M |
| KOD Kodiak Sciences Inc. compare | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$271.3M |
| IMVT Immunovant, Inc. compare | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$496.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item